Track CaliPharms's long-term debt ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
CaliPharms (KGET) currently reports a long-term debt of $0 as of September 2014. In the prior-year period, the figure was $0. Use the charts on this page to explore CaliPharms's long-term debt history and peer comparisons.
CaliPharms's long-term debt changed from $0 to $0 (period ending September 2014). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
CaliPharms reported $0 in long-term debt as of September 2014. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CaliPharms, and consider following KGET for alerts when major investors trade the stock.
CaliPharms is classified in the Industrials sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing KGET with unrelated industries.